Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the ...
LONG ISLAND, New York (WABC) -- Long Island is well represented this year at the prestigious Regeneron Science Talent Search. The annual search is the longest running of its kind, and seeks the ...
NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...
Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...
Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback